Sanofi and Regeneron's would-be blockbuster tops Humira in arthritis

Sanofi and Regeneron's would-be blockbuster tops Humira in arthritis

The treatment, sarilumab, is an antibody targeting the inflammation-related protein interleukin-6 to treat autoimmune disease. In a late-stage trial enrolling 369 patients, the therapy beat out Humira in clearing up rheumatoid arthritis symptoms after

(Visited 1 times, 1 visits today)
2
Like
Save

Comments

Comments are disabled for this post.